Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00

by · The Cerbat Gem

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its price target upped by Chardan Capital from $24.00 to $35.00 in a research note published on Monday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Other analysts also recently issued reports about the stock. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. JPMorgan Chase & Co. upped their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Canaccord Genuity Group raised their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group set a $50.00 target price on Stoke Therapeutics in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.70.

View Our Latest Analysis on STOK

Stoke Therapeutics Stock Down 0.1%

Shares of STOK stock opened at $35.17 on Monday. The stock has a 50-day simple moving average of $30.08 and a 200 day simple moving average of $23.43. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $38.69. The stock has a market capitalization of $2.01 billion, a P/E ratio of 52.49 and a beta of 1.10.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. On average, sell-side analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Activity

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 40,472 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the transaction, the director directly owned 364,246 shares in the company, valued at approximately $9,827,357.08. The trade was a 10.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 5,931 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $25.72, for a total value of $152,545.32. Following the completion of the sale, the insider owned 7,195 shares of the company’s stock, valued at $185,055.40. The trade was a 45.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 104,705 shares of company stock valued at $3,070,910. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its position in Stoke Therapeutics by 117.0% during the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after acquiring an additional 14,118 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Stoke Therapeutics in the first quarter worth approximately $2,376,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Finally, Jane Street Group LLC grew its position in Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares in the last quarter.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Featured Articles